The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.

Late-breaking findings on pulmonology, critical care, and sleep medicine will be presented at the American Thoracic Society ...

Former smokers with COPD reporting higher perceived stress had poorer scores on respiratory health assessments, according to ...

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States, most often caused by ...

New findings suggest asthma may be reversible in some cases, offering hope for long-term remission and a shift in treatment ...

Environmental factors such as lifestyle and the medications you take influence the effects your genes have on your body − and ...

Researchers at Baylor College of Medicine and collaborating institutions have uncovered a key molecular player that is ...

Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism, is a major cause of morbidity and ...

Kaminski and his colleagues were pioneers in applying high-throughput, genome-scale transcript profiling to advanced lung ...